CN1033646C - 4,13-dioxy-bicyclo (8,2,1) tridecylenone derivative, its prepn. method and its intermediate product and said compound-contained medicament - Google Patents
4,13-dioxy-bicyclo (8,2,1) tridecylenone derivative, its prepn. method and its intermediate product and said compound-contained medicament Download PDFInfo
- Publication number
- CN1033646C CN1033646C CN93100166A CN93100166A CN1033646C CN 1033646 C CN1033646 C CN 1033646C CN 93100166 A CN93100166 A CN 93100166A CN 93100166 A CN93100166 A CN 93100166A CN 1033646 C CN1033646 C CN 1033646C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- methyl
- dioxy
- bicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Ring-contracted N-demethyl-N-isopropylerythromycin A derivatives with gastrointestinally effective motilin-agonistic properties and the preparation thereof are described.
Description
The present invention relates to have and to replace (2R by the irritating new N-of therbligs, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydroxyl penta-2 '-yl)-7-((2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-examines own pyrans glycosyl)-oxygen)-9-((3,4, the 6-three deoxidations-3-amino-beta--own pyrans glycosyl of D-wood)-and oxygen)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone compound and acid salt thereof and the formula of medicine and the method and the intermediate product that prepare this compound that contain this compound.The compounds of this invention is the ring N-demethylation-N-isopropyl derivative that contracts of erythromycin.
Known antibiotic erythromycin also has except that its anti-microbial effect antibiotic disadvantageous gastrointestinal side-effect, can make gastrointestinal region strong shrinkability expansion effect occur in addition and causes gastrointestinal spasm, feels sick vomiting and diarrhoea.
Carried out many tests and adopted change erythromycin, and wherein in fact do not had anti-microbial effect, but still kept influencing the effect of gi tract motility to obtain derivative.EP 0 349100 A2 disclose some formula of medicine, wherein containing contract ring erythromycin derivatives or its quaternary salt as precursor and can strengthen gastric motility by cholinergic mechanism.
The present invention seeks to develop no antibiotic effect and to the erythromycin that the gi tract motility has the requirement effect ring derivatives that newly contracts.
The ring N-demethylation-N-isopropyl derivative that newly contracts of having found erythromycin has selectivity can the therbligs pungency, on request the motility in mode stimulating gastrointestinal road and the sphincteral tonus in oesophagus bottom had enhancement.According to its activity profile, material of the present invention is suitable for the treatment gastrointestinal tract disorder and demonstrates good consistency.
The present invention relates to formula I new (2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydro penta-2 '-yl)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone derivatives and stable medicinal acid addition salt thereof, R among the formula I
1Be methyl or hydrogen.
R in the preferred formula I compound
1Be methyl.
Formula I compounds process for production thereof can be undertaken by currently known methods, wherein can be with R among the sec.-propyl drawing-in system II
1Define the same (2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydro penta-2 '-yl)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8,2,1) 13 carbon-12-alkene-5-ketone derivatives are in case of necessity with methyl R
1Introduce R among the gained formula I
1For the compound of hydrogen or from gained formula I R
1Remove methyl R in the compound for methyl
1And in case of necessity formula I free cpds is changed into its stable acid salt or acid salt is transformed accepted way of doing sth I free cpds.
Formula II compound can be introduced sec.-propyl by the currently known methods alkylation, wherein preferably formula II compound and acetone are reacted under reductive condition and carry out reductive alkylation by currently known methods, as can be at reductive agent such as coordination hydroborate such as sodium cyanoborohydride, under triacetyl oxygen sodium borohydride or sodium borohydride exist formula II compound and acetone are reacted, in case of necessity also can be with R among the formula II
1For the compound of methyl and isopropyl halide such as isopropyl iodide or sulfuric acid isopropyl ester or the reaction of sulfonic acid isopropyl ester with its alkylation, and preferably under reaction conditions, be and carry out alkylation in the organic solvent inert, can make solvent with excessive acetone during as reductive alkylation, also available in addition cyclic ethers such as tetrahydrofuran (THF) Huo diox, aromatic hydrocarbons such as methyl or lower alcohol are made solvent, and alkylation temperature be room temperature to solvent boiling point, with isopropyl derivative such as isopropyl halide such as isopropyl iodide alkylation the time, preferably in the presence of alkali such as alkaline carbonate or uncle's organic amine, carry out.
R among the gained formula I
1For can follow-uply being alkylated into by currently known methods in case of necessity, the compound of hydrogen is corresponding N-methyl compound, wherein by carrying out alkylation or under reductive condition, carry out reductive alkylation, as under formula II alkylation condition, carrying out with formaldehyde reaction by currently known methods and methyl halide reaction.
Follow-up in case of necessity from formula I R
1Remove methyl R in the compound for methyl
1Wherein can in inert solvent, in the presence of suitable alkali, use halogen by currently known methods, particularly iodine and/or bromine are handled this compound and demethylation, and alkali can be with an alkali metal salt of for example alkali metal hydroxide and weak organic acid, preferably with taking off alkyl to avoid hydrolytic side reactions in the weakly alkaline scope below the PH9.
Formula I compound can be told from reaction mixture and purifies by currently known methods, acid salt not only can change into free alkali and free alkali but also can change into medicinal acid addition salt by currently known methods by currently known methods, and preferably only uses the angelic acid salify for fear of hydrolytic side reactions.
As formula I compound medicinal acid addition salt, available for example its inorganic acid salt such as carbonate, halogen acid salt, especially hydrochloride or organic acid salt such as lower aliphatic one or diacid salt such as maleate, fumarate, lactic acid salt, tartrate or acetate.
Formula II precursor compound is not explanation in present document.By the present invention, formula II compound is the valuable intermediate product of preparation pharmaceutical active compounds suc as formula the I compound.
Formula II compound can make with formula III erythromycin by currently known methods, wherein erythromycin earlier by currently known methods as carrying out one or two demethylations by preferably in inert solvent, in the presence of suitable alkali, reacting with iodine with halogen by DE-OS 2154032, alkali is the available bases metal hydroxides for example, alkaline carbonate and weak carboxylic acids an alkali metal salt such as alkali metal acetate or propionic salt, by the preferred adding of demethylation erythromycin compounds amount 1-5 equivalent halogen, wherein alkali number should be selected, so that pH value reaches 5-9, thereby avoid hydrolysis or alcoholysis side reaction, and should use methyl alcohol as solvent, cyclic ethers such as diox or tetrahydrofuran (THF), the mixture of dimethyl formamide or above-mentioned solvent and water, and demethylation preferably carries out in room temperature to 50 ℃, and available through quartz or constant temperature glass (as Pyrex
R) illumination of system reseau promotes to react as the illumination more than the wavelength 290nm that sends with the mercury low-voltage lamp, can after reaction, get single or two demethylation products according to used halogen quantity, when using the equivalent halogen preferably single demethylation product, and with 2 or preferential two demethylation products during many equivalents halogen, the product of available in case of necessity single demethylation is made two demethylation products.
The list of erythromycin or two demethylation products can transform R among the accepted way of doing sth IV by gentle acid treatment by currently known methods
1Be the corresponding single of hydrogen or methyl or two demethylations 8, the 9-erythromycin-6 that dewaters, the 9-hemiketal is as forming hemiketal with acetate or dilution mineral acid treatment under to about 50 ℃ in room temperature.
In formula IV compound, can shift by intermolecular lactone group and 14 yuan of lactonic rings of erythromycin structure ring that contracts is become 12 yuan of lactonic rings by known way, form corresponding formula II compound simultaneously, its Chinese style IV compound can be heated to for example 40-70 ℃ by currently known methods in the presence of alkali in lower alcohol, preferred reaction mixture boiling point, and alkali is particularly used alkaline carbonate, but also available organic bases such as tertiary amine, uncle's low-grade alkylamine particularly, and the chiral centre configuration does not change in this ring process that contracts.
Formula I compound and medicinal acid addition salt thereof have effective pharmacological, but particularly stimulating gastrointestinal road motility can therbligs pungency, there is not antibiotic effect, but to having highly selective avidity by the therbligs acceptor, and can reach effectively can therbligs do not have gi tract in the stimulating dose scope in other acceptor such as suprarenin, vagusstoff, resistance amine, the in fact significant affinity of Dopamine HCL or serum-based acceptor.
For the nutritive ingredient that guarantees to suck can be regulated digestion, autologous nerve system and gastrointestinal hormone can actings in conjunction under the state of health, thereby not only directly after sucking nutrition, and it is adjustable to reach the gi tract contractive action on an empty stomach at gi tract.Can therbligs be known gi tract peptide hormone, but stimulating gastrointestinal road motility and can on an empty stomach with suck nutrition after just whole gi tract reach co-ordinate motion.
Formula I compound has the physiological action of similar energy therbligs, therefore can be used as the synergist of energy therbligs acceptor, its Chinese style I compound is drawn together about facility to gastrointestinal region and bottom oesophagus significant hormesis, especially to quickening stomach emptying and improving esophagus continuously and draw together the rest tension of about machine effect is arranged, according to its energy therbligs class activity profile, these materials are suitable for treatment gi tract motility obstacle and/or chyme to return the disease that oesophagus causes from stomach, and formula I compound is applicable to the various causes of disease that stomach for example collapses from physical exhaustion and causes, gastric emptying disorder and stomach esophagus reflux, maldigestion, the colon motility is unusual, as situation about in irritable bowel syndrome, occurring (=supersensitivity stool syndromes is reduced into IBS) and can be used for postoperative motility obstacle as operation property intestinal occlusion (ileus).
The gi tract validity of formula I compound can be done to show with in vitro tests in the body by the pharmacology standard test methods follow-up.
The test method explanation
1. the determination test material is to the associativity of energy therbligs acceptor
Formula I compound to can therbligs a test determination of the affinity of the acceptor tissue homogenate that can in external use rabbit hole, take out, wherein carry out the competitive exclusion situation that radio-labeling iodate can the therbligs receptors bind time can therbligs by substances.
Receptors bind research by improving one's methods of Borman et al carry out (Regulatory Peptides 15 (1986), 143-153), for making
125Iodine labeling can therbligs, can be currently known methods, cross the iodate of oxygenase enzyme as method (Scand.J.Gastroenterol 11 (1976) 47-52) as described in the similar Bloomet al with breast.
Be to obtain the test tissue homogenate that takes out from the rabbit hole, can be with the refinement of mucous membrane hole and at ten times cold homogenizing damping fluid (50mM Tris-HCl damping fluid, 250mM sucrose, 25mMKCl, 10mMMg
2Cl
2PH7.4) inhibiting (1mM iodo-acid amide in, 1 μ M WHO pepstatin, 0.1mM Fumette, the 0.1g/l trypsin inhibitor is 0.25g/lBactracin) and with homogenizer homogenizing 15 seconds under 1500rpm, used the 1000g centrifugation then 15 minutes, the gained residuum repeatedly (is equivalent to 5 times of volumes to Dou Chongliang) with being suspended in the 0.9% sodium-chlor liquid after the washing of homogenizing damping fluid, and gained homogenate is called " thick film preparation liquid ", can be used for test.
In conjunction with the test in the thick film homogenate of 200 μ l (0.5-1mg albumen) at 400 μ l buffer A (50mM Tris-HCl damping fluid, 1.5%BSA, 10mMMgCl
2, PH8.0) (PH8) middle dilution (final concentration 50mM) is cultivated in 60 for back 30 ℃ for 10mMTris-HCl damping fluid, 1%BSA in buffer B with 100 μ l iodate energy therbligs.Be added dropwise in the reaction 3.2ml cold buffer liquid B and by centrifugation (1000g, 15 minutes) with combination and not the bound energy therbligs be separated from each other.Granular residuum after the centrifugation is with buffer B washing and with γ-rolling counters forward.Add being at war with property of the substances repulsion research of continuous increasing amount in developing medium, the available substances aqueous solution can be by suitably dilution 60 * 10
-4Water stoste is made, and the substances that solvability is low in water is dissolved in earlier in 60% ethanol, and with abundant water dilution, alcohol concn is no more than 1.6Vol% in the experimental liquid thereby make again.Measure the IC of each substances under different concns with the gained material
50, i.e. iodate can therbligs to can the therbligs receptor-specific in conjunction with 50% value of being obstructed, and then calculate corresponding pIC
50, record example 1 material pIC by this method
50Value is 8.32.
2. determine of the influence of these materials in the body to stomach emptying speed
The determining of stomach emptying speed measured with Beagl-Hunden, esophageal fistula wherein is provided before the test operation and has been provided with the duodenal sleeve pin, feeds 285g semi-solid state thermal test meal for the empty stomach dog that wakes through esophageal fistula in 15 minutes behind the duodenum receiving test material.The stomach ejecta was collected with the duodenal sleeve pin in 15 minutes, calculated with inventory in the stomach of collecting to reach 50% stomach emptying required time at interval, as the stomach emptying index.
Can reach significant stomach emptying at this test Chinese style I compound under 0.46 μ Mol/kg dosage stimulates, and the time of stomach 50% emptying shortens to 27 minutes that take the substances group from 4.6 minutes of comparative group.
3. the interior determination test material of body is to the influence of sphincter of gullet rest tension
Test uses the empty stomach Beagle dog that wakes of testing through instruction to carry out, and connects esophageal fistula and duodenal sleeve pin before the test, and the pressure of lower esophageal sphincter is measured with the perfusion cannula of lateral opening, and conduit links to each other with registering instrument with manometer.Conduit is manual slowly toward post-tensioning (two pull out manometry) after esophageal fistula stretches into stomach.The part of conduit band lateral opening is counted peak value by the high pressure area of bottom sphincter of gullet, with this peak value measurement mmHg pressure.
Measuring the sphincter of gullet base pressure so earlier is worth as a comparison, take substances in the duodenum then, measured the pressure of bottom sphincter of gullet at interval in per 2 minutes in 46 minutes after 15 minutes and calculate and take pressure and the base pressure that records earlier lift-off value relatively behind the trier.
It is above to double in 0.251 μ Mol/Kg example, 1 dosages of substance lower esophageal sphincter bottom tension in this test, can keep whole 45 minutes these effects of duration of test.
According to its effect in gi tract, formula I compound can be used as Mammals in gastroenterology, and particularly people's medication is used for prevention and treatment gi tract motility obstacle.
Used dosage name is inequality, certainly to as active substance content in the parenteral prescription, lack according to the state of an illness and medicine variation than oral preparations, but to taking prescription than large mammals, particularly people's with medicament, the wherein general 5-200mg/ single dose of active substance content.
When making medicine, formula I compound can be made Galenic formula such as sheet, capsule, suppository or solution with common medicinal auxiliary agent, wherein make with currently known methods, can use common solid carrier such as lactose, starch or talcum or liquid diluent such as water, grease or liquid paraffin are also with common auxiliary agent such as film-making agent, dissolve medium or preserving agent.
Following embodiment describes the present invention in detail, but does not limit the present invention.
Example 1
(2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydroxyl penta-2 '-yl)-7-(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-examines own pyrans glycosyl)-oxygen)-9-((3,4,6-three deoxidations-3-(the N-methyl-N-isopropyl third amino)-β-own pyrans glycosyl of D-wood)-oxygen)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone (R among the=formula I
1Compound for methyl)
A) preparation N-demethylation erythromycin
20g erythromycin (=27.2mmol) and 11.2g (=136.2mmol) sodium acetate is dissolved in the mixture post-heating to 47 ℃ of 200ml methanol (8: 2), adds 6.9g (=136.2mmol) iodine then.Hydro-oxidation sodium is released the aqueous solution makes the pH value keep 8-9,3 hours afterreaction mixtures are poured in the mixture that 1l water and 20ml solution of ammonium hydroxide form and are handled the back ethyl acetate extraction, organic phase is with the solution washing that contains ammonium hydroxide and concentrate, and tells residue crude product behind the organic solvent with 143-148 ℃ of acetone/solution of ammonium hydroxide (50: 3) recrystallization fusing point.
B) preparation N-demethylation-8, the 9-erythromycin-6 that dewaters, 9-hemiketal (R among the=formula IV
1Compound for methyl)
Products therefrom liquid adds reaction mixture in the 400ml ammonium hydroxide solution,stronger under ice-cold situation in 110ml acetate and after stirring 1 hour under the room temperature and handles 21gA).Reaction mixture extracts the back organic extract and washes and tell solvent with water in ethyl acetate, the residue crude product gets 14g pure products, 145 ℃ of fusing points with using recrystallizing methanol behind the ether earlier.
C) preparation (2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydroxyl penta-2 '-yl)-7-((2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-examines own pyrans glycosyl)-oxygen)-9-((3,4, the 6-three deoxidations-3-methylamino--β-own pyrans glycosyl of D-wood)-oxygen)-2,6,8,10-12-pentamethyl--4,3-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone (R among the=formula II
1Compound for methyl)
9.4g products therefrom and 1.9g in the (=13.4mmolB) (=13.4mmol) the carbonic acid clock refluxes in methyl alcohol and boils 2.5 hours reaction mixture concentration, and dilute with water is also used ethyl acetate extraction.Tell behind the solvent the residue crude product with the Virahol recrystallization and the 7.1g pure products, fusing point 199-200 ℃, curl value (α)
20D:-31.6 ° (c=1, methyl alcohol).
D) the preparation topic is shown compound
2g (=2.8mmol) above-mentioned C) products therefrom is dissolved in methyl alcohol and adds dilute hydrochloric acid solution and makes the pH value keep 4, adds 2g molecular sieve (ca aluminosilicate, aperture 4_) in solution, excessive propanone and 0.4g (=6.4mmol) sodium cyanoborohydride.Reaction mixture stirs filtering molecular sieve after 12 hours, and filtrate adds water and uses ethyl acetate extraction after concentrating.Residue crude product after acetic acid ethyl ester extract concentrates with silica gel column chromatography (eluent: ethyl acetate/methanol (95: 5)) and 1.4g inscribes and show compound, fusing point 130-134 ℃, curl value (α)
20D:-32.8 °.
Example 2
(2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydroxyl penta-2 '-yl)-7-((2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-examines own pyrans glycosyl)-oxygen)-9-((3,4,6-three deoxidations-3-(N-methyl-N-isopropyl third amino)-β-wooden own pyrans glycosyl)-oxygen)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone (being the compound of methyl among the=formula I)
A) preparation N-demethylation Erythromycin A
5g erythromycin and 4.7g sodium acetate (x3H
2O) be dissolved in the mixture of 200ml methanol (8: 2), in solution, add 1.75g iodine, steam after 20 minutes to remove half solvent and will remain reaction mixture with quartz lamp irradiation under the reaction mixture room temperature and pour in the mixture of 140ml water and 10ml ammoniacal liquor.Reaction mixture again 3 times with 20ml methyl tertiary butyl ether extraction, the ether extraction liquid tell the rear section steam remove the ether afterreaction produce crystallization and with acetone recrystallization and 2g N-demethylation erythromycin.
B) be preparation N-demethylation-8, the 9-erythromycin-6 that dewaters, 9-half ketone acetal (R among the=formula IV
1Compound for methyl) can be with 2g A) products therefrom is with routine 1B) handle and get the 2.3g amorphous solid half ketone ferment that contracts.
C) be preparation (2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-dihydroxyl penta-2 '-yl)-7-((2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-examines own pyranose glycosyl)-oxygen-9-((3,4, the 6-three deoxidations-3-methylamino--β-own pyrans glycosyl of D-wood)-oxygen)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone (R among the=formula II
1Compound for methyl) can be with the above-mentioned products therefrom of 2.3g with routine 1C) handle and make gained crude product recrystallization get the 1.3g pure products, fusing point 199-202 ℃ with ethyl acetate.D) the above-mentioned product of 1.3g adds in the mixture of 26ml acetone and 0.11ml acetate, drips 0.6g acetyl oxygen sodium borohydride in the nitrogen protection downhill reaction mixture and with reaction mixture stirring at room 4 hours.Steam then and remove 2/3rds solvents and dilute residuum with the 40ml ethyl acetate.Add the 65ml saturated sodium bicarbonate solution under fully stirring.From the clear solution that forms, tell organic phase and wash water with the 20ml ethyl acetate.The combination organic phase is with the 13ml water washing and use dried over sodium sulfate.Steaming desolventizes, and residuum adds 20ml toluene also again with its evaporation.The gained crude product is made eluent through alumina column (25gAl with ethyl acetate
2O
3, active level II/III) filter and purify.Steaming desolventizes the back residuum and is dissolved in the boiling ethyl acetate.Add normal hexane afterwards until the mixture muddiness.Allow product put cold crystallization gained xln filtration under diminished pressure and to get the 0.8g topic and show compound, fusing point 128-135 ℃ with the normal hexane washing.
E) for will change into its acetic ester can with 1g (=1.3mmol) topic shows that compound is dissolved in methyl alcohol and adds 0.08ml (=1.3mmol) removal of solvent under reduced pressure behind the acetate to solution, the topic that will form is shown compound acetic ester drying again, 145-150 ℃ of its fusing point, curl value (α)
20D:-30.8 ° (c=1, methyl alcohol).
Example I
Make the following sheet of forming:
〔2R，3R(2R′，3R′)，6R，7S，8S，10R〕-3-
(2 ', 3 '-dihydroxyl penta-2 '-yl)-((2,6-two for 7-
Deoxidation-3-C-methyl-3-0-methyl-α-L-examines own pyrans
Glycosyl)-oxygen)-9-((3,4,6-three deoxidations-3-(N-first
Base-N-isopropylamino)-β-own pyrans glycosyl of D-wood)-oxygen)
-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo
(8.2.1) 13 carbon-12-alkene-5-ketone
(R is the compound of methyl among the=formula I) 20mg
W-Gum 60mg
Lactose 135mg
Gelatin (10% solution) 6mg
With active substance, W-Gum and lactose concentrate with 10% gelatin solution, and gained is stuck with paste refinement, are poured on the suitable plate gained grain and 45 ℃ of dryings, and dry grain is by mixing in mixing tank with following auxiliary agent behind the pulverizer:
Talcum 5mg
Magnesium Stearate 5mg
W-Gum 9mg
Afterwards it is pressed into the sheet of 240mg.
Claims (2)
- Formula I (2R, 3R (2R ', 3R '), 6R, 7S, 8S, 9R, 10R)-3-(2 ', 3 '-second hydroxyl penta-2 '-yl)-2,6,8,10,12-pentamethyl--4,13-dioxy-bicyclo (8.2.1) 13 carbon-12-alkene-5-ketone derivatives and stable medicinal acid addition salt thereof,R wherein 1Be methyl.
- 2. the pharmaceutical composition of a treatment gi tract motility obstacle, especially gastric emptying disorder, this pharmaceutical composition contains compound and the common auxiliary agent and/or the carrier of medicine significant quantity claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4200145A DE4200145A1 (en) | 1992-01-07 | 1992-01-07 | 7,10-EPOXY-OXACYCLODODANE DERIVATIVES, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
| DEP4200145.5 | 1992-01-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1075320A CN1075320A (en) | 1993-08-18 |
| CN1033646C true CN1033646C (en) | 1996-12-25 |
Family
ID=6449136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93100166A Expired - Fee Related CN1033646C (en) | 1992-01-07 | 1993-01-06 | 4,13-dioxy-bicyclo (8,2,1) tridecylenone derivative, its prepn. method and its intermediate product and said compound-contained medicament |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US5418224A (en) |
| EP (1) | EP0550895B1 (en) |
| JP (1) | JP3300084B2 (en) |
| KR (1) | KR100273937B1 (en) |
| CN (1) | CN1033646C (en) |
| AT (1) | ATE155478T1 (en) |
| AU (1) | AU667699B2 (en) |
| CA (1) | CA2086811C (en) |
| CZ (1) | CZ281773B6 (en) |
| DE (2) | DE4200145A1 (en) |
| DK (1) | DK0550895T3 (en) |
| DZ (1) | DZ1652A1 (en) |
| ES (1) | ES2104808T3 (en) |
| FI (1) | FI106862B (en) |
| GR (1) | GR3024859T3 (en) |
| HK (1) | HK1014003A1 (en) |
| HU (2) | HU212272B (en) |
| IL (1) | IL104158A (en) |
| LT (1) | LT3015B (en) |
| LV (1) | LV10458B (en) |
| MX (1) | MX9300045A (en) |
| NO (1) | NO179586C (en) |
| PH (1) | PH30098A (en) |
| RU (1) | RU2107070C1 (en) |
| SK (1) | SK279251B6 (en) |
| TW (1) | TW238308B (en) |
| UA (1) | UA29393C2 (en) |
| ZA (1) | ZA9339B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100275A (en) * | 1995-10-13 | 2000-08-08 | Neurosearch A/S | 8-azabicyclo[3.2.1.]oct-2-ene derivatives, their preparation and use |
| US6077943A (en) * | 1996-03-01 | 2000-06-20 | Takeda Chemical Industries, Ltd. | Method of producing erythromycin derivative |
| AU2231097A (en) * | 1996-03-01 | 1997-09-16 | Kitasato Institute, The | Processes for the preparation of erythromycin derivatives |
| DE19644195A1 (en) * | 1996-10-24 | 1998-04-30 | Solvay Pharm Gmbh | 10,13,15-Trioxatricyclo [9.2.1.1. · 9 ·. · 6 ·] -pentadecanone derivatives, processes for their preparation and pharmaceuticals containing these compounds |
| US6165985A (en) * | 1998-02-13 | 2000-12-26 | Solvay Pharmaceuticals Gmbh | 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them |
| DE19805822B4 (en) * | 1998-02-13 | 2009-02-05 | Solvay Pharmaceuticals Gmbh | 11-Acetyl-12,13-dioxabicyclo [8.2.1] tridecenone derivatives, process for their preparation and medicaments containing these compounds |
| DE60027015T2 (en) | 2000-08-17 | 2006-10-05 | The Kitasato Institute | Pseudoerythromycin DERIVATIVES |
| EP1392679B1 (en) * | 2001-05-10 | 2005-11-02 | Solvay Pharmaceuticals GmbH | Novel 1-amidomethylcarbonyl-piperidine derivatives, method for the production thereof and medicament containing said compounds |
| US20040067896A1 (en) * | 2002-07-25 | 2004-04-08 | The Kitasato Institute | Novel pseudoerythromycin derivatives |
| WO2004111077A1 (en) | 2003-06-18 | 2004-12-23 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
| US7582611B2 (en) * | 2005-05-24 | 2009-09-01 | Pfizer Inc. | Motilide compounds |
| EP1960414A4 (en) * | 2005-12-08 | 2008-12-17 | Pfizer | Method for demethylating the 3'-dimethylamino group of erythromycin compounds |
| JP5684474B2 (en) | 2006-09-11 | 2015-03-11 | オセラ セラピューティクス， インコーポレイテッド | Macrocyclic antagonist of motilin receptor for the treatment of gastrointestinal dysmotility disease |
| ES2401467T3 (en) * | 2006-12-05 | 2013-04-19 | Bristol-Myers Squibb Company | Motilide polymorphs |
| US20080287371A1 (en) * | 2007-05-17 | 2008-11-20 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex |
| JP6295247B2 (en) * | 2013-03-25 | 2018-03-14 | ゼリア新薬工業株式会社 | Postprandial gastric motility agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725385A (en) | 1970-11-02 | 1973-04-03 | Abbott Lab | Process for the demethylation of 3-amino macrolides |
| US5106961A (en) * | 1987-05-26 | 1992-04-21 | Eli Lilly And Company | Erythromycin ring-contracted derivatives |
| CA1321581C (en) * | 1987-05-26 | 1993-08-24 | Herbert A. Kirst | Ring-contracted macrolides |
| US4920102A (en) * | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
-
1992
- 1992-01-07 DE DE4200145A patent/DE4200145A1/en not_active Withdrawn
- 1992-11-18 SK SK3414-92A patent/SK279251B6/en unknown
- 1992-11-18 CZ CS923414A patent/CZ281773B6/en not_active IP Right Cessation
- 1992-12-13 DZ DZ920162A patent/DZ1652A1/en active
- 1992-12-18 PH PH45475A patent/PH30098A/en unknown
- 1992-12-18 IL IL104158A patent/IL104158A/en not_active IP Right Cessation
- 1992-12-21 HU HU9204076A patent/HU212272B/en not_active IP Right Cessation
- 1992-12-22 LT LTIP187A patent/LT3015B/en not_active IP Right Cessation
- 1992-12-23 US US07/996,083 patent/US5418224A/en not_active Expired - Lifetime
- 1992-12-24 EP EP92122011A patent/EP0550895B1/en not_active Expired - Lifetime
- 1992-12-24 ES ES92122011T patent/ES2104808T3/en not_active Expired - Lifetime
- 1992-12-24 DE DE59208710T patent/DE59208710D1/en not_active Expired - Fee Related
- 1992-12-24 DK DK92122011.7T patent/DK0550895T3/en active
- 1992-12-24 AT AT92122011T patent/ATE155478T1/en not_active IP Right Cessation
- 1992-12-28 KR KR1019920026335A patent/KR100273937B1/en not_active IP Right Cessation
- 1992-12-30 RU RU92016224A patent/RU2107070C1/en not_active IP Right Cessation
-
1993
- 1993-01-05 ZA ZA9339A patent/ZA9339B/en unknown
- 1993-01-06 JP JP00055793A patent/JP3300084B2/en not_active Expired - Fee Related
- 1993-01-06 NO NO930029A patent/NO179586C/en unknown
- 1993-01-06 AU AU31036/93A patent/AU667699B2/en not_active Ceased
- 1993-01-06 CN CN93100166A patent/CN1033646C/en not_active Expired - Fee Related
- 1993-01-06 LV LVP-93-01A patent/LV10458B/en unknown
- 1993-01-06 CA CA002086811A patent/CA2086811C/en not_active Expired - Fee Related
- 1993-01-07 MX MX9300045A patent/MX9300045A/en not_active IP Right Cessation
- 1993-01-07 FI FI930051A patent/FI106862B/en active
- 1993-03-25 TW TW082102267A patent/TW238308B/zh active
- 1993-04-22 UA UA93002699A patent/UA29393C2/en unknown
-
1994
- 1994-09-30 HU HU94P/P00031P patent/HU210216A9/en unknown
-
1997
- 1997-09-24 GR GR970402503T patent/GR3024859T3/en unknown
-
1998
- 1998-12-17 HK HK98113965A patent/HK1014003A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1033646C (en) | 4,13-dioxy-bicyclo (8,2,1) tridecylenone derivative, its prepn. method and its intermediate product and said compound-contained medicament | |
| RU2086560C1 (en) | Macrolide compounds and pharmaceutical composition | |
| TWI232865B (en) | Crystalline clindamycin free base | |
| JP5529745B2 (en) | Novel mangoglycoside calcium salt, process for producing the same and use thereof | |
| JPS62175497A (en) | Bile acid derivative and production thereof | |
| KR100466495B1 (en) | 10,13,15-trioxatricyclo [9.2.1.19.6] -pentadecanone derivatives, preparation methods thereof, and pharmaceutical products containing the compounds | |
| CN107224577B (en) | Oligosaccharide conjugate based on streptococcus pneumoniae capsular polysaccharide type 3 and preparation method and application thereof | |
| JP3006513B2 (en) | Pharmaceutical composition | |
| WO2019179325A1 (en) | Preparation method for surface capsular polysaccharide structural derivative of gram-positive bacteria | |
| MXPA97007974A (en) | Derivatives of 10, 13, 15-trioxatriciclo [9.2.1.1 9.6] -pentadecanona, procedures for its preparation and medicines that contain these compounds | |
| CN1189473C (en) | 11-acetyl-12,13-dioxa bicyclo [8.2.1] tridecenone -derivative, its preparation and medicine containing the compound | |
| CN101812099B (en) | Flavonoids compound and synthesis method and application thereof | |
| CN102702285A (en) | Intermediates for flavonoid compounds and preparation method thereof | |
| CN101307044A (en) | Two crystallographic form of pinocembrin compounds, preparation method and applications for treating diseases | |
| JPS63132831A (en) | Antiserotonin agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: PATENTEE; FROM: KALI-CHEMIE PHARMA GMBH TO: SOLVAY PHARMA GMBH |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Solvay Pharmaceuticals GmbH Patentee before: Kali-Chemie Pharma GmbH |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |